正在加载视频...
视频加载失败
Big Pharma keeps using R&D costs to justify high launch prices even after peer-reviewed research found no association between the two. The argument persists because it protects profits and blocks reform. Rob Burgess follows the receipts.
102,084 次观看 • 2 个月前 •via X (Twitter)
0 条评论
暂无评论
原始帖子的评论将显示在这里

